Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enamelin is a large (approximately 168 kDa) non-amelogenin enamel matrix protein encoded by the ENAM gene and is essential for the proper formation of dental enamel during tooth development. It is the least abundant among enamel matrix proteins (1-5%), but it is critical for controlling the growth, elongation, and architecture of enamel crystals by interacting with hydroxyapatite and other matrix proteins in developing teeth. Enamelin undergoes extensive post-translational modification, including phosphorylation by FAM20C, and is processed by proteases such as MMP20 shortly after secretion. Mutations in the ENAM gene cause autosomal-dominant and autosomal-recessive forms of amelogenesis imperfecta, characterized by generalized thin enamel or absence of the enamel layer. It is not considered a typical drug target, enzyme, transporter, or receptor, but rather a highly specialized extracellular matrix protein essential for hard tissue mineralization in teeth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enamelin (ENAM).